EGFR causes neoangiogenesis but also increased proliferation, decreased apoptosis, and enhanced tumor cell motility [43] since its receptor (EGFR; HER1; erbB1) is highly expressed on variety of human tumors including non-small cell lung cancer (NSCLC) and breast, head and neck, gastric, colorectal, esophageal, prostate, bladder, renal, pancreatic, and ovarian cancers [42, 44]. The gene discussed is EGFR; the disease is ovarian carcinoma.